TRIAL DETAIL

Imatinib + IL-2

Drug:
Trial Name:
Imatinib + IL-2
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date
Age of Trial (yrs)
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT inhibitor + Immune stimulate
Strategy:
Block KIT + Stimulate the immune system
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
IMAIL-2 RECF0842 2007-001699-35 IGR#CSET 2007/1277#IMAIL-2
Sponsor:
Institut Gustave Roussy
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Trial Notes:
This trial is listed on the IGR Phase I list as being under Dr. P. Pautier. It may now include both solid tumors and melanoma and ovarian cancer.

Trial Links
 
 
 
 
 

Trial Results
 

Drug Information
LRG story - Opening of Gleevec + IL2 phase I trial at Gustave Roussy
 
Proleukin.com
 
LRG story- Background on Gleevec + IL2 for GIST
 
Proleukin prescribing information
 
A novel dendritic cell subset supporting the concept of tumor immunoediting: IFN producing Killer Dendritic cell (IKDC)
 
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects (PDF)
 
Natural Killer Cell IFN-{gamma} Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients
 

Trial Sites

Name
Address
City
State
Zip
Country
Villejuif
Val de Narne
94805
France